Arkolith/Insider Trading/INMB/Form 4

Ganjei James Kelly

DirectorInmune Bio, Inc. (INMB) · full profile →Form 4 · filed Nov 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
16
0 non-derivative · 16 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 18, 2025Disposed to issuer(D)35K——0
Nov 18, 2025Disposed to issuer(D)16K——0
Nov 18, 2025Disposed to issuer(D)19K——0
Nov 18, 2025Grant(A)19K——19K
Nov 18, 2025Grant(A)35K——35K
Nov 18, 2025Disposed to issuer(D)35K——0
Nov 18, 2025Grant(A)35K——35K
Nov 18, 2025Disposed to issuer(D)33K——0
Nov 18, 2025Grant(A)33K——33K
Nov 18, 2025Disposed to issuer(D)13K——0
Nov 18, 2025Grant(A)13K——13K
Nov 18, 2025Grant(A)16K——16K
Nov 18, 2025Grant(A)108K——108K
Nov 18, 2025Disposed to issuer(D)108K——0
Nov 18, 2025Grant(A)108K——108K
Nov 18, 2025Disposed to issuer(D)108K——0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-112229) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML